Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges

PLoS Pathogens

Volumn 7, Issue 5, 2011, Pages

  Im, Eung Jun ^a   Hong, Jessie P ^a   Roshorm, Yaowaluck ^a   Bridgeman, Anne ^a   Létourneau, Sven ^a   Liljeström, Peter ^b   Potash, Mary Jane ^c   Volsky, David J ^c   McMichael, Andrew J ^a   Hanke, Tomáš ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; VACCINATION; VIRUS INACTIVATION; ANIMAL; BAGG ALBINO MOUSE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV-1; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION;

EID: 79958045785     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002041     Document Type: Article

References (68)

1. Yewdell JW, (2006) Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25: 533-543.
2. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, et al. (2002) T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 3: 627-634.
3. Mo AX, van Lelyveld SF, Craiu A, Rock KL, (2000) Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J Immunol 164: 4003-4010.
4. Probst HC, Tschannen K, Gallimore A, Martinic M, Basler M, et al. (2003) Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. J Immunol 171: 5415-5422.
5. van der Most RG, Murali-Krishna K, Lanier JG, Wherry EJ, Puglielli MT, et al. (2003) Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 315: 93-102.
6. Yewdell JW, Bennink JR, (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51-88.
7. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
8. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, et al. (2002) Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415: 335-339.
9. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253-1272.
10. Goulder PJ, Watkins DI, (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4: 630-640.
11. Moore CB, John M, James IR, Christiansen FT, Witt CS, et al. (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439-1443.
12. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7: 173-178.
13. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG, (1998) Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 187: 1647-1657.
14. Liu J, Ewald BA, Lynch DM, Nanda A, Sumida SM, et al. (2006) Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol 80: 11991-11997.
15. Rodriguez F, Slifka MK, Harkins S, Whitton JL, (2001) Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities. J Virol 75: 7399-7409.
16. van der Most RG, Concepcion RJ, Oseroff C, Alexander J, Southwood S, et al. (1997) Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J Virol 71: 5110-5114.
17. von Herrath MG, Dockter J, Nerenberg M, Gairin JE, Oldstone MB, (1994) Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J Exp Med 180: 1901-1910.
18. McMichael AJ, Hanke T, (2003) HIV vaccines 1983-2003. Nat Med 9: 874-880.
19. Bridgeman A, Roshorm Y, Lockett LJ, Xu ZZ, Hopkins R, et al. (2010) Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28: 474-483.
20. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, et al. (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81: 9408-9418.
21. Nitkiewicz J, Chao W, Bentsman G, Li J, Kim SY, et al. (2004) Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture. J Neurovirol 10: 400-408.
22. Potash MJ, Chao W, Bentsman G, Paris N, Saini M, et al. (2005) A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A 102: 3760-3765.
23. Roshorm Y, Hong JP, Kobayashi N, McMichael AJ, Volsky DJ, et al. (2009) Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101+ patients protected mice against chimaeric EcoHIV challenge. Eur J Immunol 39: 1831-1840.
24. Hanke T, McMichael AJ, (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6: 951-955.
25. Im EJ, Hanke T, (2007) Short communication: preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice. AIDS Res Hum Retroviruses 23: 857-862.
26. Larke N, Im E-J, Wagner R, Williamson C, Williamson A-L, et al. (2007) Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol 37: 566-577.
27. Liu Y, McNevin J, Rolland M, Zhao H, Deng W, et al. (2009) Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. J Infect Dis 200: 1825-1833.
28. Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2: e984.
29. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, et al. (2010) Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 40: 1973-1984.
30. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L, (2007) Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol 88: 1-12.
31. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, et al. (1988) An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85: 3105-3109.
32. Hanke T, Schneider J, Gilbert SC, Hill AVS, McMichael A, (1998) DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice. Vaccine 16: 426-435.
33. Nakagawa Y, Kikuchi H, Takahashi H, (2007) Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution. Biophys J 92: 2570-2582.
34. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y, (1998) The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 161: 2985-2993.
35. Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, et al. (2004) Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22: 3395-3403.
36. Mwau M, McMichael AJ, Hanke T, (2002) Design and Validation of an ELISPOT Assay for Use in Clinical Trials of Candidate HIV Vaccines. AIDS Res Hum Retroviruses 18: 611-618.
37. Shastri N, Serwold T, Gonzalez F, (1995) Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J Immunol 155: 4339-4346.
38. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
39. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
40. Harrington LE, Most Rv R, Whitton JL, Ahmed R, (2002) Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 76: 3329-3337.
41. Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, et al. (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80: 6318-6323.
42. Hanke T, Barnfield C, Wee EG-T, Ågren L, Samuel RV, et al. (2003) Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84: 361-368.
43. Rolland M, Nickle DC, Mullins JI, (2007) HIV-1 group M conserved elements vaccine. PLoS Pathog 3: e157.
44. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) Viral Immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205-2213.
45. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. (2003) Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17: 2581-2591.
46. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. (2001) Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193: 375-386.
47. Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, et al. (2001) Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193: 181-194.
48. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10: 11-23.
49. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, et al. (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 94: 1890-1895.
50. Walker BD, Goulder PJ, (2000) AIDS. Escape from the immune system. Nature 407: 313-314.
51. Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, et al. (2007) Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204: 2187-2198.
52. Belz GT, Xie W, Altman JD, Doherty PC, (2000) A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge. J Virol 74: 3486-3493.
53. Chen W, Pang K, Masterman KA, Kennedy G, Basta S, et al. (2004) Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J Immunol 173: 5021-5027.
54. Nugent CT, McNally JM, Chervenak R, Wolcott RM, Jennings SR, (1995) Differences in the recognition of CTL epitopes during primary and secondary responses to herpes simplex virus infection in vivo. Cell Immunol 165: 55-64.
55. Hislop AD, Taylor GS, Sauce D, Rickinson AB, (2007) Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
56. Kedl RM, Schaefer BC, Kappler JW, Marrack P, (2002) T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 3: 27-32.
57. Willis RA, Kappler JW, Marrack PC, (2006) CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci U S A 103: 12063-12068.
58. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, et al. (2002) Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168: 4391-4398.
59. Yewdell JW, (2010) Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol 22: 402-410.
60. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289.
61. Bennett MS, Ng HL, Ali A, Yang OO, (2008) Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J Infect Dis 197: 390-397.
62. D'Souza MP, Altfeld M, (2008) Measuring HIV-1-specific T cell immunity: how valid are current assays? J Infect Dis 197: 337-339.
63. Le Gall S, Stamegna P, Walker BD, (2007) Portable flanking sequences modulate CTL epitope processing. J Clin Invest 117: 3563-3575.
64. Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, et al. (2009) Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 10: 636-646.
65. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med 4: 397-402.
66. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, et al. (2000) In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74: 5769-5775.
67. Valentine LE, Watkins DI, (2008) Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol 16: 605-611.
68. Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, et al. (2004) The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods 285: 25-40.